Biofilm-related infections with drug resistant bacteria are particularly difficult to treat, because the biofilm offers bacteria additional protection against antimicrobials. New strategies and compounds to fight such resilient infections are sorely needed. But the full repertoire of genes and processes that are essential for biofilm formation in different microbes is still unknown.
We want to identify anti-biofilm active substances and antibodies and construct tools to apply them genome-wide. Furthermore, we aim to characterise the mechanisms of action of these novel anti-biofilm agents.
Bacterial infections that are related to biofilms (bacterial communities that form a dense coating on diverse surfaces) are difficult to treat with current antibiotic strategies. All the more so when drug resistant bacteria are involved. We investigate new approaches in order to acquire new tools, targets and agents for understanding and treating biofilm-associated infections in four major antimicrobial resistant pathogens: Staphylococci, Pneumococci, E. coli and Pseudomonas.
This consortium project involves labs in Norway (Norwegian Unversity of Life Sciences), Switzerland (University of Lausanne) and Germany (EMBL, Heidelberg). Our project is able to screen for anti-biofilm active substances and construct tools to apply them genome-wide, based on state-of-the-art gene sequencing technologies. Finally, we shed light on how exactly the new substances work.
For more information, visit the official DISRUPT website.